Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. FibroGen (FGEN) downgraded to Sell from Neutral at Goldman Sachs with analyst Paul Choi seeing "operational uncertainty" stemming from the recent Complete Response Letter issued by the FDA for roxadustat. FibroGen will likely have to perform additional studies in order to clarify the MACE safety concerns. 2. Vir Biotechnology (VIR) downgraded to Neutral from Buy at Goldman Sachs with analyst Paul Choi saying near-term revenue from Covid-19 therapeutic antibody sotrovimab "may not be as substantial as previously modeled." 3. Hutchmed (HCM) downgraded to Neutral from Buy at Goldman Sachs with analyst Paul Choi expecting the outlook for the company's "robust portfolio of assets is largely captured by current valuations." 4. DXC Technology (DXC) downgraded to Neutral from Buy at MoffettNathanson with analyst Lisa Ellis seeing more limited upside over the next 12 months. 5. FedEx (FDX) downgraded to Market Perform from Outperform at Raymond James with analyst Patrick Tyler Brown citing a "disappointing" quarter despite solid top line trends on lower guidance, continued CapEx investments, back-end loading of guidance, and more global uncertainty. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.